The treatment and management of myeloproliferative neoplasms (MPNs) including myelofibrosis (MF) and polycythemia vera (PV) has transformed in recent years, although several challenges remain. There are ongoing clinical trials investigating the safety and efficacy of novel agents for this group of diseases, as well as strategies to improve the diagnosis and risk stratification of patients.
In this podcast, Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, Anthony Hunter, MD, Winship Cancer Institute of Emory University, Atlanta, GA, Jean-Jacques Kiladjian, MD, PhD, Saint-Louis Hospital & Paris Diderot University, Paris, France, and John Mascarenhas, MD, Mount Sinai Medical Center, New York, NY, discuss several updates in the field of MPNs. Topics covered include novel agents being explored in PV, clinical guidance for the use of JAK inhibitors in MF, and the growing role of combination approaches.
ASH 2021: a deep dive into ALL immunotherapy
ASH 2021: what did ASH 2021 mean for MDS?
ASH 2021: novel developments in MPNs
ASH 2021: evaluating the impact of screening for multiple myeloma precursor diseases
ASH 2021: the future of cell therapies in lymphoma
ASH 2021: highlights in CLL clinical trials
ASH 2021: updates in FLT3-mutated AML
The Lymphoma Sessions: post-ASH 2021
COSTEM: maintenance therapies for FLT3+ AML
COSTEM: the role of alloHSCT in ALL
SOHO 2021: amyloidosis treatment updates
IACH 2021: CAR-T in clinical practice
Unmet needs and recent updates in CML
IMW 2021: treatment-free intervals in multiple myeloma
Highlights from iwCLL 2021
IMW 2021: MRD in myeloma
CAR-T vs bispecifics: replacing ASCT in myeloma
EHA 2021: antibody therapies for NHL
EHA 2021: updates on novel agents for AML
Texas MPN Workshop 2021: updates on JAK inhibitors for MPNs
Create your
podcast in
minutes
It is Free
The Relaxback UK Show
Good Nurse Bad Nurse
On Call With Dr. Anselm Anyoha
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive